-
DESCRIPTION AND BURDEN OF PORTAL HYPERTENSION TREATMENTS IN FRANCE: A NATIONAL HOSPITAL DATABASE ANALYSIS
Aug 11, 2026, 17:16 PM -
HOW MUCH RESIDUAL BIAS WOULD OVERTURN A PER-PROTOCOL REAL-WORLD EVIDENCE CONCLUSION?
Aug 11, 2026, 17:16 PM -
DO TRADITIONAL SYSTEMATIC LITERATURE REVIEW (SLR) METHODS MEET THE STANDARDS OF TRANSPARENCY AND INCREASING AI-ASSISTED SCREENING? A CASE STUDY COMPARING INDIVIDUAL VS. HIERARCHICAL POPULATION, INTERVENTION/COMPARATOR, OUTCOMES, STUDY DESIGN (PICOS...
Aug 11, 2026, 17:16 PM -
ACCURACY AND EFFICIENCY OF A HUMAN-IN-THE-LOOP PROMPT-FEEDBACK WORKFLOW FOR ARTIFICIAL INTELLIGENCE-ENABLED EVIDENCE SYNTHESIS: A BILIARY TRACT CANCER SYSTEMATIC LITERATURE REVIEW CASE STUDY
Aug 11, 2026, 17:16 PM -
AUSTRIA'S NATIONAL EHEALTH STRATEGY: A COMPARATIVE POLICY ANALYSIS FOCUSED ON THE PREHABILITATION TO REHABILITATION PATHWAY
Aug 11, 2026, 17:16 PM -
ECONOMIC BURDEN OF DIABETES COMPLICATIONS IN ALGERIA: A REAL-WORLD BUDGET IMPACT ANALYSIS
Aug 11, 2026, 17:16 PM -
DISEASE BURDEN AND HEALTHCARE UTILIZATION AFTER DIAGNOSIS OF NEUROFIBROMATOSIS TYPE 1 AND PLEXIFORM NEUROFIBROMAS (NF1-PN) IN SWEDISH PEDIATRIC PATIENTS: A REGISTRY-BASED STUDY
Aug 11, 2026, 17:16 PM -
ECONOMIC EVALUATION OF FENOFIBRATE FOR REDUCING THE PROGRESSION OF DIABETIC RETINOPATHY IN THAILAND
Aug 11, 2026, 17:16 PM -
COST-PER-RESPONSE OF ADVANCED THERAPIES IN SPONDYLOARTHRITIS FROM THE PERSPECTIVE OF THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM
Aug 11, 2026, 17:16 PM -
COST-UTILITY OF SOX WITH BEVACIZUMAB IN COLORECTAL CANCER AMONG INDIAN POPULATION
Aug 11, 2026, 17:16 PM -
WHAT DRIVES POSITIVE NICE HEALTHTECH DECISIONS? A REVIEW OF ECONOMIC EVALUATION EVIDENCE FROM RECENT APPRAISALS
Aug 11, 2026, 17:16 PM -
EVOLUTION OF SOCIAL MEDIA CONVERSATIONS ABOUT OBESITY AND GLP-1 TREATMENTS IN FRANCE BETWEEN 2016 AND 2026 : A SOCIAL LISTENING STUDY
Aug 11, 2026, 17:16 PM -
INCREASED RATES OF EMERGENCY CARE IN PEOPLE WITH IDIOPATHIC INFLAMMATORY MYOPATHIES: A POPULATION-BASED COHORT IN ENGLAND 2002 TO 2021
Aug 11, 2026, 17:16 PM -
A FACTUAL CHECK THAT CANNOT REACH THE REASONING: THE FACTUAL-ACCURACY PARADOX
Aug 11, 2026, 17:16 PM -
COST-EFFECTIVENESS OF FINERENONE FOR CHINESE PATIENTS WITH HEART FAILURE AND LEFT VENTRICULAR EJECTION FRACTION (LVEF) ≥40...
Aug 11, 2026, 17:16 PM -
A MODEL EXPLAINER AGENT TO REDUCE THE COMPREHENSION BURDEN ON HTA ASSESSORS REVIEWING ECONOMIC MODEL SUBMISSIONS: A CASE STUDY IN RARE DISEASE
Aug 11, 2026, 17:16 PM -
EMERGING TRENDS IN HEALTH TECHNOLOGY ASSESSMENT, PRICING, AND REIMBURSEMENT: A STRUCTURED REVIEW OF 2025-2026 GLOBAL POLICY DEVELOPMENTS
Aug 11, 2026, 17:16 PM -
THE PATIENT JOURNEY IN PULMONARY FIBROSIS IN GREECE: DIAGNOSTIC PATHWAYS, DELAYS, AND EARLY MANAGEMENT
Aug 11, 2026, 17:16 PM -
DOES THE ELIGIBILITY RULE, NOT THE DRUG EFFECT, SET THE AFFORDABLE PRICE? A DIALYSIS-REVEALED COST-UTILITY ANALYSIS OF TOLVAPTAN IN ADPKD
Aug 11, 2026, 17:16 PM -
COST-EFFECTIVENESS AND UNCERTAINTY ANALYSIS OF EBOLA VACCINATION STRATEGIES IN CHILDREN AND ADOLESCENTS
Aug 11, 2026, 17:16 PM
